Selective CDK Inhibitors: Promising Candidates for Future Clinical Traumatic Brain Injury Trials

Overview

Journal Neural Regen Res

Date 2014 Nov 5

PMID 25368642

Citations 8

Authors

Shruti V Kabadi

Alan I Faden

Affiliations

Soon will be listed here.

Abstract

Traumatic brain injury induces secondary injury that contributes to neuroinflammation, neuronal loss, and neurological dysfunction. One important injury mechanism is cell cycle activation which causes neuronal apoptosis and glial activation. The neuroprotective effects of both non-selective (Flavopiridol) and selective (Roscovitine and CR-8) cyclin-dependent kinase inhibitors have been shown across multiple experimental traumatic brain injury models and species. Cyclin-dependent kinaseinhibitors, administered as a single systemic dose up to 24 hours after traumatic brain injury, provide strong neuroprotection-reducing neuronal cell death, neuroinflammation and neurological dysfunction. Given their effectiveness and long therapeutic window, cyclin-dependent kinase inhibitors appear to be promising candidates for clinical traumatic brain injury trials.

Citing Articles

Identification of cyclin D1 as a major modulator of 3-nitropropionic acid-induced striatal neurodegeneration.

Dietrich P, Alli S, Mulligan M, Cox R, Ashbrook D, Williams R Neurobiol Dis. 2021; 162:105581.

PMID: 34871739 PMC: 8717869. DOI: 10.1016/j.nbd.2021.105581.

Chronic Traumatic Encephalopathy: Update on Current Clinical Diagnosis and Management.

Pierre K, Dyson K, Dagra A, Williams E, Porche K, Lucke-Wold B Biomedicines. 2021; 9(4).

PMID: 33921385 PMC: 8069746. DOI: 10.3390/biomedicines9040415.

Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic Interventions.

Jarrahi A, Braun M, Ahluwalia M, Gupta R, Wilson M, Munie S Biomedicines. 2020; 8(10).

PMID: 33003373 PMC: 7601301. DOI: 10.3390/biomedicines8100389.

Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury.

Saha P, Gupta R, Sen T, Sen N Neurobiol Dis. 2018; 118:108-116.

PMID: 30010002 PMC: 6087674. DOI: 10.1016/j.nbd.2018.07.010.

Up-regulation of FOS-like antigen 1 contributes to neuronal apoptosis in the cortex of rat following traumatic brain injury.

Xu X, Jiang R, Gong P, Liu Q, Chen Y, Hou S Metab Brain Dis. 2017; 33(1):115-125.

PMID: 29080084 DOI: 10.1007/s11011-017-0129-7.

References

Urrea C, Castellanos D, Sagen J, Tsoulfas P, Bramlett H, Dietrich W . Widespread cellular proliferation and focal neurogenesis after traumatic brain injury in the rat. Restor Neurol Neurosci. 2007; 25(1):65-76. View

Byrnes K, Loane D, Stoica B, Zhang J, Faden A . Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury. J Neuroinflammation. 2012; 9:43. PMC: 3308916. DOI: 10.1186/1742-2094-9-43. View

Kabadi S, Stoica B, Byrnes K, Hanscom M, Loane D, Faden A . Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma. J Cereb Blood Flow Metab. 2011; 32(1):137-49. PMC: 3323296. DOI: 10.1038/jcbfm.2011.117. View

Di Giovanni S, Movsesyan V, Ahmed F, Cernak I, Schinelli S, Stoica B . Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A. 2005; 102(23):8333-8. PMC: 1149422. DOI: 10.1073/pnas.0500989102. View

Taupin P . BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation. Brain Res Rev. 2006; 53(1):198-214. DOI: 10.1016/j.brainresrev.2006.08.002. View

Hilton G, Stoica B, Byrnes K, Faden A . Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J Cereb Blood Flow Metab. 2008; 28(11):1845-59. PMC: 2718694. DOI: 10.1038/jcbfm.2008.75. View

Bramlett H, Dietrich W . Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res. 2007; 161:125-41. DOI: 10.1016/S0079-6123(06)61009-1. View

OSUGA H, Osuga S, Wang F, Fetni R, Hogan M, Slack R . Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A. 2000; 97(18):10254-9. PMC: 27851. DOI: 10.1073/pnas.170144197. View

Kabadi S, Stoica B, Loane D, Luo T, Faden A . CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014; 34(3):502-13. PMC: 3948132. DOI: 10.1038/jcbfm.2013.228. View

10.

Stoica B, Byrnes K, Faden A . Cell cycle activation and CNS injury. Neurotox Res. 2009; 16(3):221-37. DOI: 10.1007/s12640-009-9050-0. View

11.

Long J, Kalehua A, Muth N, Calhoun M, Jucker M, Hengemihle J . Stereological analysis of astrocyte and microglia in aging mouse hippocampus. Neurobiol Aging. 1999; 19(5):497-503. DOI: 10.1016/s0197-4580(98)00088-8. View

12.

Byrnes K, Faden A . Role of cell cycle proteins in CNS injury. Neurochem Res. 2007; 32(10):1799-807. DOI: 10.1007/s11064-007-9312-2. View

13.

Greene L, Biswas S, Liu D . Cell cycle molecules and vertebrate neuron death: E2F at the hub. Cell Death Differ. 2003; 11(1):49-60. DOI: 10.1038/sj.cdd.4401341. View

14.

Nutley B, Raynaud F, Wilson S, Fischer P, Hayes A, Goddard P . Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther. 2005; 4(1):125-39. View

15.

Nguyen M, Boudreau M, Kriz J, Couillard-Despres S, Kaplan D, Julien J . Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci. 2003; 23(6):2131-40. PMC: 6741997. View

16.

Bettayeb K, Baunbaek D, Delehouze C, Loaec N, Hole A, Baumli S . CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer. 2011; 1(4):369-80. PMC: 3092200. DOI: 10.1177/1947601910369817. View

17.

Chirumamilla S, Sun D, Bullock M, Colello R . Traumatic brain injury induced cell proliferation in the adult mammalian central nervous system. J Neurotrauma. 2002; 19(6):693-703. DOI: 10.1089/08977150260139084. View

18.

Cernak I, Stoica B, Byrnes K, Di Giovanni S, Faden A . Role of the cell cycle in the pathobiology of central nervous system trauma. Cell Cycle. 2005; 4(9):1286-93. DOI: 10.4161/cc.4.9.1996. View

19.

Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott J, Galons H . CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008; 27(44):5797-807. DOI: 10.1038/onc.2008.191. View

20.

Meijer L, Borgne A, Mulner O, Chong J, J Blow J, Inagaki N . Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997; 243(1-2):527-36. DOI: 10.1111/j.1432-1033.1997.t01-2-00527.x. View